MTOR and neoplasm: HIF-1 also increases oncogene activity through the inactivation of tumor suppressors (e.g., VHL) and through PI3K/AKT/mTOR in cancer cells, ultimately driving cancer progression and metabolic alterations that are resistant to treatment (145).